Skip to main content
Cureus logoLink to Cureus
. 2021 Sep 30;13(9):e18409. doi: 10.7759/cureus.18409

Castleman Disease Presenting as a Mediastinal Mass

Sebastian Garcia 1, Jerry Fan 1,
Editors: Alexander Muacevic, John R Adler
PMCID: PMC8555930  PMID: 34729285

Abstract

Castleman disease is a complex benign lymphoproliferative disorder characterized by the enlargement of a single lymph node or a group of lymph nodes. Its etiology is unclear, with the mechanism of action of IL-6 and HHV-8 implicated as possibly associated with the development of the disease. Diagnosis depends on the histopathological findings of the involved lymph nodes. Surgical resection can be curative, but a small number of cases may be unresectable and need radiation and chemotherapy with subsequent resection if possible.

Keywords: castleman disease, lymphoproliferative disorder, mediastinal mass, unicentric, multicentric

Introduction

Castleman disease (CD) is a rare lymphoproliferative disorder characterized by the involvement of lymph nodes [1]. CD can be classified on the basis of the involvement of a single lymph node (or a single region of lymph nodes) (unicentric CD (UCD)) versus multiple regions of lymph nodes (multicentric CD (MCD)) [2]. CD can be difficult to diagnose as histology and pathology from the biopsy are not unique to CD but can also be present in other disease processes. We present a case of a previously healthy male who developed a large mediastinal mass consistent with CD that did not respond to chemotherapy or radiation.

Case presentation

A 25-year-old male with a history of type 1 diabetes mellitus presented to the hospital with a two-month history of shortness of breath, wheezing, chest tightness, and palpitations, which was treated with albuterol and prednisone without significant improvement. He subsequently developed odynophagia, night sweats, and occasional diarrhea, and he lost 20 lb of weight. He underwent a chest computed tomography (CT), which revealed a large mediastinal mass measuring 8.2 cm within the subcarinal region with internal calcification, compression, and narrowing of the right main pulmonary artery and left mainstem bronchus (Figure 1).

Figure 1. Chest CT demonstrating large mediastinal mass measuring 8.2 cm.

Figure 1

Left: axial

Right: coronal

Endobronchial ultrasound with biopsy and cervical mediastinoscopy were performed, but cytology was inadequate for diagnostic purposes. A video-assisted thoracoscopic surgery biopsy with adequate tissue revealed prominent follicular components composed of hyalinized germinal centers surrounded by linear arrays of mantle zone cells (onion skin). Prominent stromal components between those follicles, which are composed of many small lymphocytes associated with increased blood vessels and fibrosis, were also noted. These features were characteristic of a hyaline vascular variant of Castleman disease. Flow cytometry was nondiagnostic with mixed T- and B-lymphocytes with a polyclonal B-lymphoid predominance (Figure 2).

Figure 2. Histological sections of the subcarinal mass specimen showing features of Castleman disease.

Figure 2

The lesion has a prominent follicular component composed of hyalinized germinal centers surrounded by linear arrays of mantle zone cells (the so-called “onion skin”). In addition, there is a prominent stromal component between these follicles that is composed of many small lymphocytes associated with increased blood vessels and fibrosis.

Unfortunately, due to significant vascular involvement and adherence to critical structures, the mass was deemed to be unresectable. He underwent chemotherapy with rituximab and then cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with radiation but had minimal response.

Discussion

Castleman disease (CD) is a rare lymphoproliferative disorder distinguished by two distinct forms: unicentric and multicentric [1]. Unicentric CD (UCD) involves a single lymph node or a single region of lymph nodes, while multicentric CD (MCD) involves multiple areas of enlarged lymph nodes [1]. UCD is often asymptomatic unless the mass compresses critical structures, causing secondary symptoms [2]. UCD is more common in the mediastinum but can occur in lymph nodes from any area of the body, including the axilla, neck, retroperitoneum, or abdomen [3].

The pathogenesis of UCD remains unclear, but viral, inflammatory, and neoplastic mechanisms have been proposed by investigators to be associated with the development of the disease [1]. IL-6 dysregulation has been proposed to be the mechanism of the development of CD [4]. IL-6 is involved in the differentiation of lymphocytes, production of acute-phase reactants, angiogenesis, and tumorigenesis [4]. Patients with CD can have elevated levels of IL-6 that normalize with the removal of the involved lymph nodes [4]. HHV-8 has also been implicated in the development of CD [5].

CD can be difficult to diagnose. IL-6 levels and the presence of human immunodeficiency virus should be evaluated as dysregulation of IL-6 and susceptibility of human herpesvirus-8 in those with human immunodeficiency virus are implicated in the development of CD [6]. Biopsy is the gold standard for the diagnosis of CD, and microscopic examination helps differentiate UCD “hyaline vascular variant” from MCD “plasma cell variant” [6,7].

Treatment for CD mainly involves surgical removal of the mass, which is usually curative [8]. Unfortunately, some patients may experience compression or adhesion of critical vessels or organs, as was evident in our patient, making surgical resection impossible. In these circumstances, radiation therapy could be used as adjuvant therapy in hopes of shrinking the tumor prior to surgical resection [8-10]. Our patient underwent radiation therapy and treatment with rituximab and subsequently CHOP. Unfortunately, he had minimal response to therapy and is currently in a long-term acute care hospital recovering from respiratory failure.

Conclusions

Castleman disease is often difficult to diagnosis as it remains asymptomatic until a significant mass effect causes secondary symptoms. A tissue biopsy is essential to the diagnosis of Castleman disease.

Acknowledgments

We would like to extend a thank you to Liping Wang for her assistance in annotating the histopathological slides.

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

The authors have declared that no competing interests exist.

Human Ethics

Consent was obtained or waived by all participants in this study

References

  • 1.Castleman disease pathogenesis. Fajgenbaum DC, Shilling D. Hematol Oncol Clin North Am. 2018;32:11–21. doi: 10.1016/j.hoc.2017.09.002. [DOI] [PubMed] [Google Scholar]
  • 2.The role of surgical resection in unicentric Castleman's disease: a systematic review. Mitsos S, Stamatopoulos A, Patrini D, George RS, Lawrence DR, Panagiotopoulos N. Adv Respir Med. 2018;86:36–43. doi: 10.5603/ARM.2018.0008. [DOI] [PubMed] [Google Scholar]
  • 3.Surgery in Castleman's disease: a systematic review of 404 published cases. Talat N, Belgaumkar AP, Schulte KM. Ann Surg. 2012;255:677–684. doi: 10.1097/SLA.0b013e318249dcdc. [DOI] [PubMed] [Google Scholar]
  • 4.Castleman's disease: from basic mechanisms to molecular therapeutics. El-Osta HE, Kurzrock R. Oncologist. 2011;16:497–511. doi: 10.1634/theoncologist.2010-0212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Pathology of Castleman disease. Wu D, Lim MS, Jaffe ES. Hematol Oncol Clin North Am. 2018;32:37–52. doi: 10.1016/j.hoc.2017.09.004. [DOI] [PubMed] [Google Scholar]
  • 6.Diagnosis and management of Castleman disease. Abramson JS. J Natl Compr Canc Netw. 2019;17:1417–1419. doi: 10.6004/jnccn.2019.5037. [DOI] [PubMed] [Google Scholar]
  • 7.Clinicopathological comparison and therapeutic approach to Castleman disease-a case-based review. Wojtyś M, Piekarska A, Kunc M, et al. J Thorac Dis. 2019;11:4859–4874. doi: 10.21037/jtd.2019.10.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.The management of Castleman's disease of the mediastinum: a case report. Hountis P, Dedeilias P, Douzinas M. Cases J. 2008;1:330. doi: 10.1186/1757-1626-1-330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Clinical, laboratory and imaging findings in Castleman's disease - the subtype decides. Haap M, Wiefels J, Horger M, Hoyer A, Müssig K. Blood Rev. 2018;32:225–234. doi: 10.1016/j.blre.2017.11.005. [DOI] [PubMed] [Google Scholar]
  • 10.Castleman's disease and radiotherapy: a single center experience. Uysal B, Demiral S, Gamsiz H, Dincoglan F, Sager O, Beyzadeoglu M. J Cancer Res Ther. 2015;11:170–173. doi: 10.4103/0973-1482.140766. [DOI] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES